Citations

Clear

3314 citation(s) found for "Yu, Alexander".

Adult Brachial Plexus Injuries: Treatment in the Acute Phase
Rodriguez, Maria Cristina, Shin, Alexander Y.

Mayo Clinic

Cirugía de Mano y Microcirugía | July 4, 2024 | Volume: 3 | Issue: 1 | Pages: No page available

10.25214/28056272.1678 Get It

Brachial Plexus Injuries are a catastrophic situation that affects patients on many levels. While many treatment options are discussed in the literature, general treatment principles should be applied, especially in the acute phase. In addition to the surgeon's expert knowledge of anatomy and injury characteristics, education of the patient concerning the ramifications of their injury and providing clear expectations of realistic outcomes are imperative for both the surgeon and the patient. A review of the principles of acute surgical treatment will be presented.
CheMo4METPANC: A randomized phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) compared to chemotherapy alone in metastatic
Manji, Gulam A. , Chalabi, Morteza Hajkarim, Pellicciotta, Ilenia, Ana, Sarah Sta , Sender, Naomi , Pan, Samuel , Ross, Isabelle, Wang, Shikun , Izar, Benjamin , Wu, Linda, May, Michael S. , Labadie, Brian , Bates, Susan E. , Shi, Qian , Raufi, Alexander G.

Mayo Clinic

Journal of Clinical Oncology | July 3, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS4208-TPS4208

10.1200/jco.2024.42.16_suppl.tps4208 Get It

TPS4208 Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) carries a 5-year relative survival of 3%. Immune checkpoint inhibitors have thus far failed to improve outcomes due to an immunosuppressive tumor microenvironment (TME). Signaling through the C-X-C motif chemokine receptor 4 (CXCR4)/C-X-C motif chemokine ligand 12 (CXCL12) axis results in exclusion of anti-tumor immune cells in mouse PDAC models. Longitudinal survival studies testing combinations of CXCR4i, aPD-1, and gemcitabine in the KPC mouse model of PDAC demonstrated a survival benefit with the combination of all three agents. Results from a multicenter, investigator-initiated, single arm pilot study evaluating the preliminary safety and efficacy ofMotixafortide (CXCR4i), Cemiplimab (aPD1), Gemcitabine, and Nab-paclitaxel (MCGN) in 11 patients with treatment-naïve mPDAC were recently presented. Seven patients (64%) achieved a partial response, including 6 confirmed partial responses, and 10 patients (91%) had disease control, compared to historic partial response and disease control rates of 23% and 48%, respectively, with gemcitabine and nab-paclitaxel (GN). Preliminary median progression-free survival (PFS) was 9.6 months compared to historic median PFS of 5.5 months with GN. Analysis of paired pre- and on-treatment biopsy samples from demonstrated an increase in CD8+ T-cell density in tumors from all 11 patients treated with MCGN (p=0.007). Based on these promising results, the protocol was amended from a single arm expansion totaling 40 patients to a randomized phase 2 study. Methods: This is an open-label, multicenter, investigator-initiated phase 2 clinical trial. Patients are randomized 2:1 to receive MCGN or GNalone (N=108). The primary endpoint is progression free survival. The study has 80% power to detect an improvement in PFS from 6 to 9.2 months (HR 0.65) with a one-sided alpha of 0.20. One interim analysis for futility is planned when 50% of the PFS events are observed. Secondary objectives include response rate, disease control rate, duration of clinical benefit and overall survival. Patients will undergo optional paired biopsies which will be analyzed in conjunction with samples collected from the phase I pilot study. Exploratory studies include interrogation of the TME using quantitative multiplex immunofluorescence and single-cell RNA sequencing. The randomized phase 2 trial is open to enrollment and one patient has been randomized as of 1/29/2024. Clinical trial information: NCT04543071 .
Claims-based analysis of treatment practices of patients with metastatic gastroenteropancreatic neuroendocrine tumors (mGEP-NET) in the USA.
Pavel, Marianne, Abraham, Ivo, Bernhardt, Dirk, Abraham, Ivo, Hálfdánarson, Þorvarður R. , Princic, Nicole

Mayo Clinic

Journal of Clinical Oncology | July 3, 2024 | Volume: 42 | Issue: 16_suppl | Pages: e16286-e16286

10.1200/jco.2024.42.16_suppl.e16286 Get It

e16286 Background: GEP-NET is a rare disease with variable tumor biology. An indolent disease course with subtle symptoms renders timely diagnosis difficult; 2/3 of patients (pts) are diagnosed at locally advanced or metastasized stage. In clinical decision-making, disease-specific factors, patient (pt) age and long-term disease control must be balanced against the aggressiveness of therapies. NCCN, NANETS and ENETS guidelines recognize the diversity of mGEP-NET by recommending individualized treatment approaches. We aimed to describe treatment (Tx) utilization patterns in mGEP-NET. Methods: Retrospective cohort study using MarketScan® Commercial and Medicare Databases spanning 07/01/2017-01/31/2023. Eligible were GEP-NET pts with ≥1 inpatient or ≥2 outpatient claims, a subsequent new diagnosis of metastatic disease (index), no secondary malignancy, and follow-up time of ≥12 months (m) after index. Results: Of 16218 GEP-NET pts, 2002 (mean age 60y; 50% female) met inclusion criteria. Mean follow-up time after index was 17m, with 49%, 27% and 15% followed up for ≥12, 24 and 36m, resp. Medical history (12m baseline before index) included mean Charlson Comorbidity Index of 2.62, with hypertension (HTN), type 2 diabetes (T2DM), chronic liver disease (CLD), asthma/COPD, cardiovascular disease (CVD), and chronic kidney disease (CKD) present in 56, 26, 22, 18, 17 and 10% of pts, resp.; 5% had carcinoid syndrome. In total, 949 pts (47.4%) received first-line (1L) systemic Tx: somatostatin analogs (SSA; 61.6%) of either very short or long duration (median 116d vs 775d), chemotherapy (38.8%), targeted therapies (3.4%) and PRRT (0.5%). Relative to NCCN cancer surveillance guidelines, 49.5% received more and 36.8% received fewer than 4 scans in the first year of treatment. Conversely, 1053 (52.6%) did not receive any 1L systemic Tx. With the exception of CLD, pts with vs without 1L Tx had similar proportions of medical conditions during the 12m baseline and during follow-up (HTN 72.4 vs 66.5%; T2DM 34.0 vs 30.3%; asthma/COPD 16.5 vs 19.3%; CVD 27.3 vs 36.9%; CKD 18.9 vs 17.9%; however, CLD 54.0 vs 36.7%). See Table comparing both cohorts on insurance, treatments, and health care utilization during follow-up. Conclusions: This claims analysis reveals treatment differences among mGEP-NET pts that cannot be explained by the parameters assessed herein. Further research should investigate factors influencing diagnosis and treatment decision-making, applying also pt-level health record data; and analyze economic barriers to diagnosis and treatment. [Table: see text]
Targeting IL-1 controls refractory pityriasis rubra pilaris
Schmauch, Eloi , Severin, Yannik , Xing, Xianying , Mangold, Aaron R. , Conrad, Curdin , Johannsen, Pål, Kahlenberg, J. Michelle , Mellett, Mark , Navarini, Alexander A. , Nobbe, Stefan , Nilsson, Jakob , Linna-Kuosmanen, Suvi , Snijder, Berend , Contassot, Emmanuel , Kolios, Antonios G.A. , Mangold, A R , Johansen, Pål , Navarini, Alexander , Sarkar, Mrinal K , Satyam, Abhigyan , Tsoi, Lam C , French, Lars E , Nilsson, Jakob , Linna-Kuosmanen, Suvi , Kaikkonen, Minna U , Snijder, Berend , Kellis, Manolis , Gudjonsson, Johann E , Tsokos, George C. , Contassot, Emmanuel , Kolios, Antonios G A , Kahlenberg, J Michelle , Sarkar, Mrinal K. , Tsoi, Lam C.

Mayo Clinic

Science Advances | July 3, 2024 | Volume: 10 | Issue: 27 | Pages: No page available

10.1126/sciadv.ado2365 | PMID 38959302 Get It

Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disease with a poorly understood pathogenesis. Through a molecularly driven precision medicine approach and an extensive mechanistic pathway analysis in PRP skin samples, compared to psoriasis, atopic dermatitis, healed PRP, and healthy controls, we identified IL-1β as a key mediator, orchestrating an NF-κB–mediated IL-1β–CCL20 axis, including activation of CARD14 and NOD2. Treatment of three patients with the IL-1 antagonists anakinra and canakinumab resulted in rapid clinical improvement and reversal of the PRP-associated molecular signature with a 50% improvement in skin lesions after 2 to 3 weeks. This transcriptional signature was consistent with in vitro stimulation of keratinocytes with IL-1β. With the central role of IL-1β underscoring its potential as a therapeutic target, our findings propose a redefinition of PRP as an autoinflammatory keratinization disorder. Further clinical trials are needed to validate the efficacy of IL-1β antagonists in PRP.
Differences in Right Heart Function After Pulmonary Valve Replacement in Patients With Pulmonary Valve Stenosis Versus Tetralogy of Fallot
Egbe, Alexander C. , Jain, C. Charles , Abozied, Omar , Burchill, Luke J. , Younis, Ahmed , Karnakoti, Snigdha , Ahmed, Marwan H. , Connolly, Heidi M. , Burchill, Luke J , Younis, Ahmed , Ahmed, Marwan H.

Mayo Clinic

Journal of the American Heart Association | July 3, 2024 | Volume: 13 | Issue: 14 | Pages: No page available

10.1161/jaha.124.034833 | PMID 38958134 Get It

Background There are limited data about the impact of timing of pulmonary valve replacement (PVR) on right heart reverse remodeling in patients with pulmonary regurgitation following intervention for isolated pulmonary valve stenosis (PS). This study compared differences in postprocedural right heart reverse remodeling after early versus late PVR (defined as PVR before versus after attainment of the conservative consensus criteria proposed by Bokma et al, 2018) in patients with prior intervention for PS, using patients with tetralogy of Fallot as the reference group. Method and Results Right atrial reservoir strain and right ventricular free wall strain was measured at baseline, 1 and 3 years after PVR. There were 114 patients with PS (early PVR, 87 [76%]; late PVR, 27 [24%]) and 291 patients with tetralogy of Fallot (early PVR, 197 [67%]; late PVR, 96 [33%]). The PS group had greater improvement in right atrial reservoir strain at 1 year (12%±4% versus 8%±4%; P <0.001) and 3 years (15%±6% versus 9%±6%; P <0.001), and a greater improvement in right ventricular free wall strain at 1 year (12%±4% versus 7%±3%, P =0.008) and 3‐years (16%±6% versus 12%±5%; P =0.01) after PVR compared with the tetralogy of Fallot group. There was no difference in right heart reverse remodeling between patients who underwent early versus later PVR within the PS group. In contrast, late PVR was associated with less right heart reverse remodeling within the tetralogy of Fallot group. Conclusions These data suggest that patients with palliated PS presenting pulmonary regurgitation have a more benign clinical course, and hence delaying PVR in this population may be appropriate.
Haemodynamic Contributors to Pulmonary Hypertension Across the Spectrum of Adult Congenital Heart Disease
Reddy, Yogesh N.V. , Miranda, William R. , Jain, C. Charles , Egbe, Alexander C. , Jain, Christopher C, Nishimura, Rick , Borlaug, Barry A.

Mayo Clinic

European Journal of Heart Failure | July 3, 2024 | Volume: 26 | Issue: 11 | Pages: 2356-2366

10.1002/ejhf.3366 | PMID 38956982 Get It

Abstract Aims Adult congenital heart disease (ACHD) includes multiple disease states that predispose to pulmonary hypertension (PH). Haemodynamically, PH depends on abnormalities in three components: pulmonary blood flow (Qp), pulmonary vascular resistance (PVR) and pulmonary venous pressure (PVP). We sought to evaluate the prevalence and prognostic impact of individual haemodynamic abnormalities in ACHD. Methods and results Retrospective study of ACHD patients undergoing cardiac catheterization at Mayo Clinic between 1999 and 2022 who were followed for the combined endpoint of death/heart transplantation. Among 1005 patients, 37% had mean pulmonary artery pressure (mPAP) ≥25 mmHg with more systemic ventricular disease, cyanotic disease and shunt lesions, highest N-terminal pro-B-type natriuretic peptide and worse right heart remodelling/dysfunction. Among those with biventricular circulation, elevated PVP, PVR and mPAP were associated with prognosis, but not increased Qp &gt;8 L/min. However, risk of death/transplant increased for PVR only at ≥3 Wood units (hazard ratio [HR] 3.00, 95% confidence interval [CI] 2.17–4.15; p &lt; 0.0001) and for mPAP only at ≥25 mmHg (HR 3.15, 95% CI 2.17–4.58; p &lt; 0.0001), not at current recommended lower cutpoints. Combined abnormalities in PVP and PVR were associated with worst outcome (HR 5.20, 95% CI 3.55–7.63; p &lt; 0.0001) with intermediate risk with either abnormality (HR 2.11, 95% CI 1.46–3.04; p &lt; 0.0001). Findings were consistent across type of biventricular ACHD. Only with the Fontan (univentricular) circulation was a lower mPAP threshold (20 mmHg) associated with adverse outcomes. Conclusions Elevation of mPAP ≥25 mmHg in ACHD with a biventricular circulation is prognostically important regardless of disease phenotype, but milder PH of 21–25 mmHg is not associated with adverse outcome unless associated with Fontan circulation. Elevation in PVP &gt;15 mmHg and PVR ≥3 Wood units were each individually associated with mortality with combined abnormalities associated with greatest risk. Categorizing PH in ACHD by haemodynamic mechanism (PVR, PVP or Qp) allows meaningful prognostication, and may allow more unified study of targeted therapies across heterogeneous disease states in ACHD.
Exploring systemic treatment approaches for advanced pure large cell neuroendocrine carcinoma (LCNEC): A multicenter retrospective analysis.
Matteson, Kelsey, Ardeshir, Fatemeh, Gray, Jhanelle E. , Espinar, Javier Baena , Grohé, Christian , Pancirer, Danny, Cheung, Justin Matthew, Watson, Alexander, Kaldas, David , Kim, Chul , Awosika, Nichola, Chiang, Anne C. , Nassar, Amin H. , Kwiatkowski, David J. , Nana, Frank Aboubakar , Citarella, Fabrizio , Sridhar, Arthi , Crowley, Fionnuala , Sankar, K. Nathan , Naqash, Abdul Rafeh

Mayo Clinic

Journal of Clinical Oncology | June 28, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 8106-8106

10.1200/jco.2024.42.16_suppl.8106 Get It

8106 Background: Due to lack of prospective data, the optimal first line treatment approach for patients (pts) with pure LCNEC histology remains uncertain. Methods: Across 17 centers, we conducted a retrospective analysis of metastatic pure LCNEC (diagnosed at local institutions) who received 1st-line systemic therapy between 2015-2023. Pts were either treated with chemotherapy (chemo), immunotherapy (IO), or a combination (chemoIO). Clinical outcomes were progression-free survival (PFS), overall survival (OS), objective response rates (ORR), and treatment-related adverse events (trAE) as defined using CTCAE 5.0. Survival analysis by genomic alteration status ( TP53, RB1, STK11, KEAP1, KRAS) and PD-L1 status were performed. Results: We identified 161 pts with median age of 67 years (IQR: 58-83) at 1st line systemic therapy; 54% (n = 87) were males. Median follow-up was 55 months (mo), 62 mo, and 29 mo for the chemo, IO, and chemoIO groups, respectively. 79% (n = 127) were former or current smokers. 1st-line treatments were chemo (n = 94), IO (n = 11), or chemoIO (n = 56). Of 85 pts with PD-L1 status, 58 (68%) were 0% and 27 (32%) were ≥1%. The most common chemo regimen was platinum-etoposide (n = 72, 78%). ChemoIO regimens included carboplatin/etoposide/atezolizumab (n = 23, 43%) and carboplatin/pemetrexed/pembrolizumab (n = 17, 31%). In the IO group, 1 patient received dual IO. Lung (n = 74, 46%) and liver (n = 71, 41%) were the most common sites of metastasisThere was no significant difference in PFS across the groups (median PFS [mPFS] chemoIO: 5.7 mo, 95% CI: 5.0-6.3, chemo: 5.1 mo, 95% CI: 3.1-5.9; IO: 3.6 mo, 95% CI: 1.7-6.5) on multivariable analysis adjusting for ECOG and “M” stage (p = 0.2 and 0.24 for chemoIO-chemo and chemoIO-IO comparisons, respectively). There was no difference in OS (mOS chemo: 11 mo, 95% CI: 7.6-17.4; IO: 13.6 mo, 95% CI: 5.9-not reached; chemoIO: 12.2 mo, 95% CI: 7.4-20.6, p = 0.5 and 0.8 for chemoIO-chemo and chemoIO-IO comparisons, respectively). ORR was 35.2% (31/88) in chemo, 25% (2/8) in IO, and 35.7% (20/56) in chemoIO ( p= 0.46). There were no significant differences in PFS and OS outcomes by treatment group when divided by genetic profile (n = 79, methods), or by PD-L1 status (0% vs ≥1%). Any grade trAE occurred in 48 (51%), 5 (45%), and 28 (50%) pts treated with chemo, IO, and chemoIO, respectively. Grade ≥3 toxicity profiles are shown (table). Conclusions: For 1st-line treatment of LCNEC, similar PFS, OS, and ORR were seen for chemo, IO, and chemoIO. This questions the added benefit of chemoIO compared to chemo alone, and warrants future clinical trials to discern the optimal 1st line treatment. [Table: see text]
The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD
DeFilipp, Zachariah , Spyrou, Nikolaos , Katsivelos, Nikolaos , Kowalyk, Steven, Eng, Gilbert, Kasikis, Stelios, Beheshti, Rahnuma, Baez, Janna , Akahoshi, Yu , Ayuk, Francis, Choe, Hannah , Etra, Aaron , Vášová, Ingrid, Young, Rachel , Holler, Ernst , Ferrara, James L.M. , Nakamura, Ryotaro , Chen, Yi‐Bin , Katsivelos, Nikolaos , Akahoshi, Yu , Hexner, Elizabeth , Hogan, William J , Qayed, Muna , Reshef, Ran , Nakamura, Ryotaro , Levine, John E , Chen, Yi-Bin , Kim, Haesook T. , Grupp, Stephan A. , Hexner, Elizabeth O. , Hogan, William J. , Kitko, Carrie L. , Reshef, Ran , Zeiser, Robert , Levine, John E.

Mayo Clinic

Blood Advances | June 28, 2024 | Volume: 8 | Issue: 13 | Pages: 3488-3496

10.1182/bloodadvances.2024012561 | PMID 38640197 Get It

Abstract The significance of biomarkers in second-line treatment for acute graft-versus-host disease (GVHD) has not been well characterized. We analyzed clinical data and serum samples at the initiation of second-line systemic treatment of acute GVHD from 167 patients from 17 centers of the Mount Sinai Acute GVHD International Consortium (MAGIC) between 2016 and 2021. Sixty-two patients received ruxolitinib-based therapy, whereas 102 received other systemic agents. In agreement with prospective trials, ruxolitinib resulted in a higher day 28 (D28) overall response Frate than nonruxolitinib therapies (55% vs 31%, P = .003) and patients who received ruxolitinib had significantly lower nonrelapse mortality (NRM) than those who received nonruxolitinib therapies (point estimates at 2-year: 35% vs 61%, P = .002). Biomarker analyses demonstrated that the benefit from ruxolitinib was observed only in patients with low MAGIC algorithm probabilities (MAPs) at the start of second-line treatment. Among patients with a low MAP, those who received ruxolitinib experienced significantly lower NRM than those who received nonruxolitinib therapies (point estimates at 2-year: 12% vs 41%, P = .016). However, patients with high MAP experienced high NRM regardless of treatment with ruxolitinib or nonruxolitinib therapies (point estimates at 2-year: 67% vs 80%, P = .65). A landmark analysis demonstrated that the relationship between the D28 response and NRM largely depends on the MAP level at the initiation of second-line therapy. In conclusion, MAP measured at second-line systemic treatment for acute GVHD predicts treatment response and NRM. The outcomes of patients with high MAP are poor regardless of treatment choice, and ruxolitinib appears to primarily benefit patients with low MAP.
Glycolysis in hepatic stellate cells coordinates fibrogenic extracellular vesicle release spatially to amplify liver fibrosis
Khanal, Shalil , Liu, Yuanhang , Wixom, Alexander Q. , Washington, Alexander M. , Jalan‐Sakrikar, Nidhi , Cooper, Shawna A. , Vučković, Ivan , Zhang, Song , Zhong, Jun , Johnson, Kenneth L. , Charlesworth, M. Cristine , Kim, I.Y. , Yeon, Yubin, Yoon, Sangwoong , Noh, Yung‐Kyun , Meroueh, Chady , Timbilla, Abdul Aziz , Yaqoob, Usman , Gao, Jinhang , Kim, Yohan , Hay, Nissim , Shah, Vijay H. , Bamidele, Adebowale O , Wixom, Alexander Q , Washington, Alexander M , Sakrikar, Nidhi Jalan , Cooper, Shawna A , Vuckovic, Ivan , Zhang, Song , Zhong, Jun , Johnson, Kenneth , Kim, Iljung , Yeon, Yubin , Yoon, Sangwoong , Noh, Yung-Kyun , Meroueh, Chady , Timbilla, Abdul Aziz , Gao, Jinhang , Kim, Yo Han , Lucien, Fabrice , Simons, Michael , Shah, Vijay H , Kostallari, Enis , Liu, Yuanhang, Bamidele, Adebowale O. , Charlesworth, M. Cristine , Yaqoob, Usman , Lucien, Fabrice , Huebert, Robert C. , Simons, Michael , Kostallari, Enis

Mayo Clinic

Science Advances | June 28, 2024 | Volume: 10 | Issue: 26 | Pages: No page available

10.1126/sciadv.adn5228 | PMID 38941469 Get It

Liver fibrosis is characterized by the activation of perivascular hepatic stellate cells (HSCs), the release of fibrogenic nanosized extracellular vesicles (EVs), and increased HSC glycolysis. Nevertheless, how glycolysis in HSCs coordinates fibrosis amplification through tissue zone-specific pathways remains elusive. Here, we demonstrate that HSC-specific genetic inhibition of glycolysis reduced liver fibrosis. Moreover, spatial transcriptomics revealed a fibrosis-mediated up-regulation of EV-related pathways in the liver pericentral zone, which was abrogated by glycolysis genetic inhibition. Mechanistically, glycolysis in HSCs up-regulated the expression of EV-related genes such as Ras-related protein Rab-31 ( RAB31 ) by enhancing histone 3 lysine 9 acetylation on the promoter region, which increased EV release. Functionally, these glycolysis-dependent EVs increased fibrotic gene expression in recipient HSC. Furthermore, EVs derived from glycolysis-deficient mice abrogated liver fibrosis amplification in contrast to glycolysis-competent mouse EVs. In summary, glycolysis in HSCs amplifies liver fibrosis by promoting fibrogenic EV release in the hepatic pericentral zone, which represents a potential therapeutic target.